Proper regulation and expression of major histocompatibility complex class II (MHC-II) genes is critical to developing and maintaining an active and healthy immune system. The goals of this program are to understand the molecular mechanisms responsible for their regulation. In particular this research program seeks to understand the role of chromatin in the regulation of MHC-II genes. We present data that show that the current paradigm whereby the proximal WXY regulatory motifs, which bind RFX, CREB, NF-Y and CIITA is incomplete in two ways. The first is that the paradigm does little to understand the relationship between chromatin modifications at MHC-II promoters and expression. The master regulator of MHC-II transcription CIITA coordinates most of the chromatin modifications at MHC-II promoters. However, little is known about how this occurs.
Aim 1 seeks to determine: the timing of the modifications, the relationships between the remodeling factors and CIITA, and what role the modifications have on MHC-II gene expression. Secondly, the paradigm does not include elements that regulate or coordinate expression through changes in nuclear architecture or structure. We provide evidence that we have discovered one such element. A region termed XL9, located in the intergenic space between HLA-DRB1 and HLA-DQA1, does not possess enhancer function, but is highly acetylated, interacts with the nuclear matrix, functions as an enhancer block, and is the nexus of two long range chromatin loops with the promoter regions of the above HLA genes. Moreover, XL9 binds CCCTC transcription factor (CTCF) a factor associated with chromatin insulator function and genomic imprinting. Knockdown of CTCF activity reduces expression of HLA-DRB1. The data suggest that XL9 functions to separate and coordinate the expression of the flanking MHC-II genes. The HLA-DRB1 and HLA-DQA1 genes are the first immune system genes known to be regulated by CTCF.
Aim 2 will characterize the exact role of XL9 in regulating MHC-II expression. CIITA was required for interactions with XL9 and preliminary data suggests that CIITA interacts with CTCF. We propose to examine these interactions and identify the factors associated with this complex. Such components are likely to link the biological activities of chromatin remodeling events observed with the biology of MHC-II regulation. While extremely novel in its activity, we suggest that other XL9-like elements will regulate MHC-II genes.
Aim 3 is designed to identify additional MHC-II promoter interactions and XL9-like elements with in the MHC-II region. The results from this work should provide a comprehensive view of the chromatin dynamics of MHC-II regulation and provide novel mechanisms of gene control that will be applicable to many immune system genes. Such mechanisms should provide novel targets for future immune based therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM047310-15
Application #
7775092
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Carter, Anthony D
Project Start
1993-08-01
Project End
2011-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
15
Fiscal Year
2010
Total Cost
$342,702
Indirect Cost
Name
Emory University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Scharer, Christopher D; Blalock, Emily L; Barwick, Benjamin G et al. (2016) ATAC-seq on biobanked specimens defines a unique chromatin accessibility structure in naïve SLE B cells. Sci Rep 6:27030
Barwick, Benjamin G; Scharer, Christopher D; Bally, Alexander P R et al. (2016) Plasma cell differentiation is coupled to division-dependent DNA hypomethylation and gene regulation. Nat Immunol 17:1216-1225
Kannarkat, G T; Cook, D A; Lee, J-K et al. (2015) Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control Study. NPJ Parkinsons Dis 1:
Scharer, Christopher D; Choi, Nancy M; Barwick, Benjamin G et al. (2015) Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment. Nucleic Acids Res 43:3128-42
Kasinski, Andrea; Dong, Xueyuan; Khuri, Fadlo R et al. (2014) Transcriptional regulation of YWHAZ, the gene encoding 14-3-3?. PLoS One 9:e93480
Majumder, Parimal; Scharer, Christopher D; Choi, Nancy M et al. (2014) B cell differentiation is associated with reprogramming the CCCTC binding factor-dependent chromatin architecture of the murine MHC class II locus. J Immunol 192:3925-35
Lohsen, S; Majumder, P; Scharer, C D et al. (2014) Common distal elements orchestrate CIITA isoform-specific expression in multiple cell types. Genes Immun 15:543-55
Kannarkat, George T; Boss, Jeremy M; Tansey, Malú G (2013) The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis 3:493-514
Choi, Nancy M; Boss, Jeremy M (2012) Multiple histone methyl and acetyltransferase complex components bind the HLA-DRA gene. PLoS One 7:e37554
Zinzow-Kramer, W M; Long, A B; Youngblood, B A et al. (2012) CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments. Genes Immun 13:299-310

Showing the most recent 10 out of 40 publications